Next Article in Journal
Combined Methylome and Transcriptome Analyses Reveals Potential Therapeutic Targets for EGFR Wild Type Lung Cancers with Low PD-L1 Expression
Next Article in Special Issue
Inflammasome Sensor NLRP1 Confers Acquired Drug Resistance to Temozolomide in Human Melanoma
Previous Article in Journal
Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study
Previous Article in Special Issue
Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000–2016
Open AccessEditorial

Targeted Therapies for Melanoma

by 1,2,*, 1,2,3 and 1,2,3
1
Institute of Anatomy, 1st Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic
2
BIOCEV, 1st Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic
3
Department of Dermatovenereology, 1st Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(9), 2494; https://doi.org/10.3390/cancers12092494
Received: 31 August 2020 / Accepted: 1 September 2020 / Published: 3 September 2020
(This article belongs to the Special Issue Targeted Therapies for Melanoma)
The incidence of cutaneous malignant melanoma is increasing worldwide. Despite available modern therapeutical options, long-term survival of patients in advanced stages of the disease remains rather limited until now. Detailed insights into etiopathogenesis and mechanisms of tumour progression enable physicians to manipulate distinct molecular structures and pathways therapeutically and so treat the tumour. Unfortunately, the acquisition of therapeutic resistance frequently terminates these therapeutical interventions. The presented special issue is focusing on the research and therapeutic experience of leading scientists, and it summarises the state of the art of targeted therapy of melanoma and suggests the new perspectives of the treatment of disease.
Note: In lieu of an abstract, this is an excerpt from the first page.

The incidence of cutaneous malignant melanoma (CMM) is significantly increasing worldwide.[...] View Full-Text
Keywords: melanoma; BRAF V600 mutation; advanced therapy of melanoma; therapeutic resistance melanoma; BRAF V600 mutation; advanced therapy of melanoma; therapeutic resistance
MDPI and ACS Style

Smetana, K., Jr.; Lacina, L.; Kodet, O. Targeted Therapies for Melanoma. Cancers 2020, 12, 2494.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop